Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. (CARE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00731224
Recruitment Status : Completed
First Posted : August 8, 2008
Last Update Posted : March 28, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : October 2011
  Study Completion Date : October 2011